During the quarter, the health care sector was the biggest contributor to Fund performance. Health care companies overall reported strong earnings in the first half, showing continued growth momentum. Among our health care holdings, Sinopharm Group (HKSE:01099), one of China’s largest pharmaceutical products distributors, and Sino Biopharmaceutical (HKSE:01177) were top contributors. We believe Sinopharm is among the strongest firms in its industry, and benefits most from the sector’s rapid growth.
From Matthews China Fund (Trades, Portfolio)’s Q3 2014 Commentary.
